Surface Modification of Hydroxyapatite Coating for Enhanced Antibiotic Therapy

A major strategy to combat implant-associated infections is to develop implant coatings with intrinsic antibacterial activity. Since hydroxyapatite (HAp) coatings and antibiotic administration are commonly used in clinical settings, developing HAp-coated implants with localized antibiotic-releasing properties has attracted popularity. Considering the antibacterial metal species (Ag, Zn, Cu, etc.) in metal–organic frameworks and their drug delivery capacity, in this study, a gentamicin-loaded zeolitic imidazolate framework-8 nanolayer was deposited on a plasma-sprayed HAp coating (HAp/ZIF-8@Gent), which served as a Gent and Zn2+ reservoir. The investigation on the binding interaction between ZIF-8 and HAp indicated that the growth of ZIF-8 was through a Zn2+ seed layer on the HAp coating via an adsorption–replacement mechanism, instead of simple physical adsorption. The HAp/ZIF-8@Gent coating exhibited a sustained drug-release property, and the cumulative concentration of released Gent reached 239.8 ± 7.1 μg/mL on day 8. Compared to the HAp-Zn and HAp/ZIF-8 coatings, the HAp/ZIF-8@Gent coating exhibited significantly higher antibacterial activity against E. coli. This was ascribed to the combined antibacterial effects of Zn2+ and Gent. The cytocompatibility of the HAp/ZIF-8@Gent coating was confirmed via cell proliferation. Above all, the ZIF-8-modified HAp coating with localized delivery of Gent and Zn2+ possessed excellent antibacterial activity and acceptable cytocompatibility, showing potential in mitigating implant-associated infections.